Trials of pharmacological interventions for Tourette Syndrome: A systematic review

Karen Waldon, Jonathan Hill, Cristiano Termine, Umberto Balottin, Andrea Eugenio Cavanna

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Introduction: Gilles de la Tourette Syndrome (GTS) is a childhood-onset hyperkinetic movement disorder defined by the chronic presence of multiple motor tics and at least one vocal tic and often complicated by co-morbid behavioural problems. The pharmacological treatment of GTS focuses on the modulation of monoaminergic pathways within the cortico-striato-thalamo-cortical circuitry. This paper aims to evaluate the efficacy and safety profiles of pharmacological agents used in the treatment of tics in patients with GTS, in order to provide clinicians with an evidence-based rationale for the pharmacological treatment in GTS. Method: In order to ascertain the best level of evidence, we conducted a systematic literature review to identify double-blind randomised controlled trials of medications in GTS populations. Results: We identified a large number of pharmacological agents as potentially effective in improving tic symptoms. The alpha-2 agonist Clonidine is amongst the agents with the most favourable efficacy-versus-adverse events ratio, especially in patients with co-morbid attention-deficit hyperactivity disorder, although effect sizes vary evidence-based studies. Discussion: Our results are in line with the findings of uncontrolled open-label studies. However, most trials have low statistical power due to the small sample sizes, and newer agents, such as Aripiprazole, have not been formally tested in double-blind randomised controlled trials. Further research should focus on better outcome measures, including Quality of Life instruments.

Original languageEnglish
Pages (from-to)265-273
Number of pages9
JournalBehavioural Neurology
Volume26
Issue number4
DOIs
Publication statusPublished - 2013

Fingerprint

Tics
Tourette Syndrome
Pharmacology
Randomized Controlled Trials
Hyperkinesis
Movement Disorders
Clonidine
Attention Deficit Disorder with Hyperactivity
Sample Size
Therapeutics
Quality of Life
Outcome Assessment (Health Care)
Safety
Research
Population

Keywords

  • Drug therapy
  • movement disorder
  • pharmacological treatment
  • randomised controlled trial
  • tics
  • Tourette Syndrome

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Clinical Neurology
  • Neurology

Cite this

Trials of pharmacological interventions for Tourette Syndrome : A systematic review. / Waldon, Karen; Hill, Jonathan; Termine, Cristiano; Balottin, Umberto; Cavanna, Andrea Eugenio.

In: Behavioural Neurology, Vol. 26, No. 4, 2013, p. 265-273.

Research output: Contribution to journalArticle

Waldon, Karen ; Hill, Jonathan ; Termine, Cristiano ; Balottin, Umberto ; Cavanna, Andrea Eugenio. / Trials of pharmacological interventions for Tourette Syndrome : A systematic review. In: Behavioural Neurology. 2013 ; Vol. 26, No. 4. pp. 265-273.
@article{0e27e6dce1654b12bb47dd29fffa8bed,
title = "Trials of pharmacological interventions for Tourette Syndrome: A systematic review",
abstract = "Introduction: Gilles de la Tourette Syndrome (GTS) is a childhood-onset hyperkinetic movement disorder defined by the chronic presence of multiple motor tics and at least one vocal tic and often complicated by co-morbid behavioural problems. The pharmacological treatment of GTS focuses on the modulation of monoaminergic pathways within the cortico-striato-thalamo-cortical circuitry. This paper aims to evaluate the efficacy and safety profiles of pharmacological agents used in the treatment of tics in patients with GTS, in order to provide clinicians with an evidence-based rationale for the pharmacological treatment in GTS. Method: In order to ascertain the best level of evidence, we conducted a systematic literature review to identify double-blind randomised controlled trials of medications in GTS populations. Results: We identified a large number of pharmacological agents as potentially effective in improving tic symptoms. The alpha-2 agonist Clonidine is amongst the agents with the most favourable efficacy-versus-adverse events ratio, especially in patients with co-morbid attention-deficit hyperactivity disorder, although effect sizes vary evidence-based studies. Discussion: Our results are in line with the findings of uncontrolled open-label studies. However, most trials have low statistical power due to the small sample sizes, and newer agents, such as Aripiprazole, have not been formally tested in double-blind randomised controlled trials. Further research should focus on better outcome measures, including Quality of Life instruments.",
keywords = "Drug therapy, movement disorder, pharmacological treatment, randomised controlled trial, tics, Tourette Syndrome",
author = "Karen Waldon and Jonathan Hill and Cristiano Termine and Umberto Balottin and Cavanna, {Andrea Eugenio}",
year = "2013",
doi = "10.3233/BEN-2012-120269",
language = "English",
volume = "26",
pages = "265--273",
journal = "Behavioural Neurology",
issn = "0953-4180",
publisher = "HINDAWI LTD",
number = "4",

}

TY - JOUR

T1 - Trials of pharmacological interventions for Tourette Syndrome

T2 - A systematic review

AU - Waldon, Karen

AU - Hill, Jonathan

AU - Termine, Cristiano

AU - Balottin, Umberto

AU - Cavanna, Andrea Eugenio

PY - 2013

Y1 - 2013

N2 - Introduction: Gilles de la Tourette Syndrome (GTS) is a childhood-onset hyperkinetic movement disorder defined by the chronic presence of multiple motor tics and at least one vocal tic and often complicated by co-morbid behavioural problems. The pharmacological treatment of GTS focuses on the modulation of monoaminergic pathways within the cortico-striato-thalamo-cortical circuitry. This paper aims to evaluate the efficacy and safety profiles of pharmacological agents used in the treatment of tics in patients with GTS, in order to provide clinicians with an evidence-based rationale for the pharmacological treatment in GTS. Method: In order to ascertain the best level of evidence, we conducted a systematic literature review to identify double-blind randomised controlled trials of medications in GTS populations. Results: We identified a large number of pharmacological agents as potentially effective in improving tic symptoms. The alpha-2 agonist Clonidine is amongst the agents with the most favourable efficacy-versus-adverse events ratio, especially in patients with co-morbid attention-deficit hyperactivity disorder, although effect sizes vary evidence-based studies. Discussion: Our results are in line with the findings of uncontrolled open-label studies. However, most trials have low statistical power due to the small sample sizes, and newer agents, such as Aripiprazole, have not been formally tested in double-blind randomised controlled trials. Further research should focus on better outcome measures, including Quality of Life instruments.

AB - Introduction: Gilles de la Tourette Syndrome (GTS) is a childhood-onset hyperkinetic movement disorder defined by the chronic presence of multiple motor tics and at least one vocal tic and often complicated by co-morbid behavioural problems. The pharmacological treatment of GTS focuses on the modulation of monoaminergic pathways within the cortico-striato-thalamo-cortical circuitry. This paper aims to evaluate the efficacy and safety profiles of pharmacological agents used in the treatment of tics in patients with GTS, in order to provide clinicians with an evidence-based rationale for the pharmacological treatment in GTS. Method: In order to ascertain the best level of evidence, we conducted a systematic literature review to identify double-blind randomised controlled trials of medications in GTS populations. Results: We identified a large number of pharmacological agents as potentially effective in improving tic symptoms. The alpha-2 agonist Clonidine is amongst the agents with the most favourable efficacy-versus-adverse events ratio, especially in patients with co-morbid attention-deficit hyperactivity disorder, although effect sizes vary evidence-based studies. Discussion: Our results are in line with the findings of uncontrolled open-label studies. However, most trials have low statistical power due to the small sample sizes, and newer agents, such as Aripiprazole, have not been formally tested in double-blind randomised controlled trials. Further research should focus on better outcome measures, including Quality of Life instruments.

KW - Drug therapy

KW - movement disorder

KW - pharmacological treatment

KW - randomised controlled trial

KW - tics

KW - Tourette Syndrome

UR - http://www.scopus.com/inward/record.url?scp=84874054690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874054690&partnerID=8YFLogxK

U2 - 10.3233/BEN-2012-120269

DO - 10.3233/BEN-2012-120269

M3 - Article

C2 - 22713420

AN - SCOPUS:84874054690

VL - 26

SP - 265

EP - 273

JO - Behavioural Neurology

JF - Behavioural Neurology

SN - 0953-4180

IS - 4

ER -